Actively Recruiting
Open-Label Phase 2 Study of Lifileucel in Adults With Previously Treated Advanced Soft Tissue Sarcoma
Led by Iovance Biotherapeutics, Inc. · Updated on 2026-10-09
80
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of lifileucel, a tumor-infiltrating lymphocyte treatment, in adults with advanced soft tissue sarcoma who have already received prior therapy. This study focuses on participants with unresectable or metastatic undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma who have progressed after previous treatments, including anthracycline-based regimens. The trial is a Phase 2, multicenter, open-label study aiming to assess this treatments effect on these challenging sarcomas. Participants will first undergo surgery to remove tumor tissue needed to manufacture lifileucel. The treatment regimen includes a preparative nonmyeloablative lymphodepleting regimen with cyclophosphamide and fludarabine for up to 5 days to reduce lymphocytes, followed by a single lifileucel infusion. After this, participants receive up to 4 days of aldesleukin to enhance the activity of the infused cells. The study treatment is delivered in a single group without placebo comparison. During the study, participants will have regular visits every 6 weeks for the first 6 months, then every 3 months for up to 5 years after the lifileucel infusion. Assessments include tumor measurements according to RECIST criteria, safety evaluations, and monitoring of response rates and survival outcomes. Researchers will observe objective response rate as the primary outcome and collect data on complete response, disease control, progression-free survival, overall survival, and adverse events over 5 years.
CONDITIONS
Brief Title
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma
Research Team
I
Iovance Biotherapeutics Study Team
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here